张泽伟,吴珊珊,黄丽娜,黄少楷,蔡旭镇
ZHANG Zewei,WU Shanshan,HUANG Lina,HUANG Shaokai,CAI Xuzhen

• 1:中山大学附属揭阳市人民医院药学部

摘要(Abstract)：

目的基于全社会角度,比较异甘草酸镁及还原型谷胱甘肽作为起始药物治疗抗肿瘤药物相关性急性肝损伤的成本-效果。方法回顾性收集2015~2016年某院住院治疗181例抗肿瘤药物相关性急性肝损伤患者的疗效和成本,建立决策树模型进行成本-效果分析,并采用单因素敏感性分析检验结果的稳定性。结果与还原型谷胱甘肽组比较,异甘草酸镁组期望成本较高,但期望效果更好,增量成本-效果比(ICER)为6 522.09元,敏感性分析显示结果可靠。结论异甘草酸镁作为起始药物治疗抗肿瘤药物相关性急性肝损伤具有成本-效果优势。
OBJECTIVE To evaluate the cost effectiveness of Magnesium isoglycyrrhizinate compared with Glutathione as initial treatment of antineoplastic drugs-induced acute liver injury.METHODS Retrospective data of efficacy and cost were collected from181 patients with acute liver injury induced by antineoplastic in the People's Hospital of Jieyang from 2015 to 2016.A decision tree model was constructed to analyze the data.The one-way sensitivity analysis was carried out to evaluate the stability of results.RESULTS Compared with Glutathione treatment group,Magnesium isoglycyrrhizinate treatment group gained more expect effective,but expect cost was higher,the incremental cost-effectiveness ratio(ICER) was 6 522.09 Yuan.The sensitivity analysis showed the result was stable.CONCLUSION Magnesium isoglycyrrhizinate for initial treatment of antineoplastic drugs-induced acute liver injury has cost-effective advantage.

关键词(KeyWords)： 异甘草酸镁;肿瘤;药物性肝损伤;决策树模型;成本-效果分析
magnesium isoglycyrrhizinate;neoplasms;drug induced liver injury;decision tree model;cost-effectiveness analysis

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 张泽伟,吴珊珊,黄丽娜,黄少楷,蔡旭镇
ZHANG Zewei,WU Shanshan,HUANG Lina,HUANG Shaokai,CAI Xuzhen

参考文献(References)：

• [1]任张青,王进海,郭晓燕,等.2005~2014年我国药物性肝损伤临床综合分析[J].药物流行病学杂志,2016,25(5):284-289.
• [2]于世英,姚阳.肿瘤药物相关性肝损伤防治专家共识(2014版)[M].北京:协和医科大学出版社,2014:1-43.
• [3]中国临床肿瘤学会,中华医学会血液学分会,中国抗淋巴瘤联盟.血液病患者药物性肝损伤的预防和规范化治疗专家共识(2016年版)[J].中华血液学杂志,2016,37(6):441-452.
• [4]中华医学会肝病学分会药物性肝病学组.药物性肝损伤诊治指南[J].实用肝脏病杂志,2017,20(2):257-274.
• [5]郭秀丽,姚士伟,张峻,等.异甘草酸镁联合还原型谷胱甘肽治疗化疗药物性肝损伤临床疗效观察[J].实用肝脏病杂志,2014,17(6):575-578.
• [6]郑于珠,张西,蒋莎莎,等.异甘草酸镁联合多烯磷脂酞胆碱治疗化疗药物性肝损害的临床疗效观察[J].中国医药指南,2013,11(23):668-669.
• [7]孙桂君,王艳.6种用药方案治疗化疗药物相关性肝损害的经济学评价[J].中国药房,2009,20(17):1281-1283.
• [8]闫潇琦,安爱军.三种保肝药物治疗化疗药物性肝损害的药物经济学分析[J].中国医学创新,2013,10(10):157-158.
• [9]雒维花.3种方案预防抗肿瘤药物所致肝损害的最小成本分析[J].中国药房,2008,19(29):2249-2251.
• [10]中国药物经济学评价指南课题组.中国药物经济学评价指南(2011版)[J].中国药物经济学,2011,6(3):6-48.
• [11]李倩,马爱霞.Tree Age Pro软件在医药卫生决策分析中的应用[J].中国药物经济学,2014,9(1):15-18.
• [12]刘美岑,郭丽珍,沈洁,等.恶性肿瘤化疗药物性肝损伤109例临床特点分析[J].福建医药杂志,2014,36(1):24-27.
• [13]汤丽娜,林峰,沈赞,等.异甘草酸镁治疗抗肿瘤药物引起的急性药物性肝损伤的Ⅲ期临床试验[J].肿瘤,2012,32(9):738-743.
• [14]刘丽娜,赵建学,陆玮婷.138例药物性肝损伤患者影响预后的因素分析[J].实用肝脏病杂志,2015,18(2):160-163.
• [15]孙杰,孙利华.社会意愿支付法确定成本-效果阈值的实施[J].中国卫生经济,2016,35(5):19-21.
• [16]房澍名,龚新雷,秦叔逵.新型甘草酸制剂防治抗肿瘤药物肝损伤的现状和进展[J].临床肿瘤学杂志,2013,18(9):833-841.
• [17]孙元珏,祁伟祥,姚阳.还原型谷胱甘肽与肿瘤化疗相关性肝损伤的防治[J].中国肿瘤,2015,24(1):57-63.
• [18]杨翠翠,张丽霄,秦静静,等.从不同决策主体角度测算分析药物性肝损伤的相关成本[J].中国药房,2017,28(8):1023-1026.
• [19]李特,陈蓉,李静蓉,等.保肝降酶方案治疗丙氨酸氨基转移酶升高的慢性乙型肝炎的经济学评价[J].中国药房,2013,24(46):4321-4324.